Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate is AFM13, a natural killer cell bispecific antibody (TandAb) that completed Phase I clinical trial for the treatment of various CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The company’s product candidates also include AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia; and AFM21, a TandAb program in preclinical development that binds epidermal growth factor receptor v...
Im Neuenheimer Feld 582
Founded in 2000
Affimed N.V. Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 10:55 AM
Sep 23 15
Affimed N.V. Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 10:55 AM. Venue: Le Parker Meridien Hotel, New York, New York, United States. Speakers: Adi Hoess, Chief Executive Officer and Member of Management Board.
Affimed N.V. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015
Aug 4 15
Affimed N.V. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company’s revenue was €2,210,000 against €687,000 last year. Operating loss was €4,967,000 against operating income of €7,198,000 last year. Loss before taxes was €5,184,000 against income before tax of €13,395,000 last year. Net loss was €5,184,000 or €0.19 per undiluted and diluted share against net income of €13,354,000 or €0.90 per undiluted and diluted share last year. The decrease is primarily related to the fact that prior to the corporate reorganization at the time of the IPO in September 2014, share-based payments were accounted for as liabilities with fair value adjustments each quarter. The revenue in the second quarter of 2015 was mainly attributable to revenue recognition upon achievement of milestones pursuant to the Leukemia & Lymphoma Society (LLS) collaboration and provision of research and development services provided to Amphivena.
For the six months, the company’s revenue was €4,748,000 against €1,409,000 last year. Operating loss was €6,969,000 against €2,116,000 last year. Loss before taxes was €6,668,000 against €2,320,000 last year. Net loss was €6,668,000 or €0.26 per undiluted and diluted share against €2,292,000 or €0.15 per undiluted and diluted share last year. Net cash flow used in operating activities was €7,848,000 against €3,497,000 a year ago. Purchase of intangible assets was €6,000 against €23,000 a year ago. Purchase of leasehold improvements and equipment were €82,000 against €19,000 a year ago. The increase was mainly due to higher research and development (R&D) and general and administrative-related (G&A) expenses compared to the same period last year.
Affimed N.V. to Report Q2, 2015 Results on Aug 04, 2015
Jul 28 15
Affimed N.V. announced that they will report Q2, 2015 results on Aug 04, 2015